E1505 - Synopsis for Patients
ECOG trial number
ECOG E1505
Protocol title
A Phase III Randomized Trial of Adjuvant Chemotherapy With or Without Bevacizumab for Patients With Completely Resected Stage IB (>/= 4 cm) - IIIA Non-Small-Cell Lung Cancer (NSCLC)
Principal investigator
Dr. William Solomon, MD
Contacts
Please call the study coordinator:
- Susanne Fryd at 718- 270-7366
Description
Patients will be eligible with this study after complete surgical resection of lung cancer. Patients will get one of the three standard chemotherapy regimens and will be assigned by chance to receive either a placebo or bevacizumab.
Purpose of study
Bevacizumab has been approved for treatment of advanced stage non-small-cell lung cancer; this study will test the benefit of adding bevacizumab after surgical treatment.
You can be in the study if you are
- over the age of 18
- have recently been diagnosed with lung cancer
- have had/ or going to have a resection of the lung cancer.
To find out if you could be included in this study, please call
Susanne Fryd at 718-270-7366.
We will be happy to go over the eligibility criteria with you in details.
Non-Small-Cell Lung Cancer - ECOG E1505 - Patient Version
Updated: May 22, 2008
____________________________________________________________________________________________
About us | About clinical trials | About cancer treatments | Staff / contacts | Directions | Useful links | Site map
SUNY Downstate MB-CCOP: Bringing state-of-the-art cancer clinical trials to Brooklyn.
Copyright © 2008. All rights reserved.
